Current status and perspectives in peptide receptor radiation therapy

Current Pharmaceutical Design

Volumn 15, Issue 21, 2009, Pages 2453-2462

  Ansquer, Catherine ^a,b   Kraeber Bodéré, Françoise ^a,b   Chatal, Jean François ^c  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b Team 12   (France)

^c Cyclotron ARRONAX   (France)

Author keywords

Bombesin; Cholecystokinin; Gastrin; Peptide receptor radiation therapy; PRRT; Radiolabelled peptides; Somatostatin analogues; Targeted radiotherapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ANGIOPEPTIN 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Y 90; ANTINEOPLASTIC AGENT; BOMBESIN AGONIST LU 177; BOMBESIN DERIVATIVE; CAPECITABINE; INDIUM 111 GLUCAGON LIKE PEPTIDE; LUTETIUM 177; MINIGASTRIN Y 90; NEUROKININ 1 RECEPTOR; NEUROPEPTIDE Y RECEPTOR; NEUROTENSIN DERIVATIVE; NEUROTENSIN IN 111; OCTREOTIDE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE LU 177; OCTREOTIDE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE Y 90; PASIREOTIDE; PENTETREOTIDE; PENTETREOTIDE IN 111; SCLEROPROTEIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TOPOTECAN; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE; VITRONECTIN RECEPTOR; YTTRIUM 90;

BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HAIR LOSS; HUMAN; IMAGE QUALITY; INSULINOMA; ISOTOPE LABELING; KIDNEY FAILURE; LIVER METASTASIS; LIVER TOXICITY; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PEPTIDE RECEPTOR RADIATION THERAPY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; RADIOISOTOPE THERAPY; REVIEW; SCINTIGRAPHY; STOMACH TUMOR; TESTIS DISEASE; VOMITING;

HUMANS; NEOPLASMS; NEUROENDOCRINE TUMORS; RADIOPHARMACEUTICALS; RECEPTORS, PEPTIDE; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 69249158314     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788682262     Document Type: Review

References (98)

1. Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumours. Cancer Res 1997; 57: 1377-86.
2. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001; 28: 836-46.
3. Reubi JC. Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 2004; 80 (Suppl 1): 51-6.
4. Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005; 46 (Suppl 1): 67S-75S.
5. Reubi JC Peptide receptor expression in GEP-NET. Virchows Arch 2007; 451(Suppl 1): S47-50.
6. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20: 157-98.
7. O'Toole D, Hentic O, Corcos O, Ruszniewski P. Chemotherapy for gastro-enteropancreatic endocrine tumours. Neuroendocrinology 2004; 80(Suppl 1): 79-84.
8. de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocrine-Related Cancer 2003; 10: 451-58.
9. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Mäcke HR. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27: 273-82.
10. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-31.
11. Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999; 86: 944-48.
12. Bukowski RM, Tangen CM, Peterson RF, Taylor SA, Rinehart JJ, Eyre HJ, et al. Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. Cancer 1994; 73: 1505-8.
13. Ritzel U, Leonhardt U, Stockmann F, Ramadori G. et al. Treatment of metastasized midgut carcinoids with dacarbazine. Am J Gastroenterol 1995; 90: 627-31.
14. Andreyev HJ, Scott-Mackie P, Cunningham D, Nicolson V, Norman AR, Badve SS, et al. Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors. J Clin Oncol 1995; 13: 1486-92.
15. Neijt JP, Lacave AJ, Splinter TA, Taal BG, Veenhof CH, Sahmoud T, et al. Mitoxantrone in metastatic apudomas: A phase II study of the EORTC Gastro-Intestinal Cancer Cooperative group. Br J Cancer 1995; 71: 106-8.
16. Ansell SM, Pitot HC, Burch PA, Kvols LK, Mahoney MR, Rubin J, et al. A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 2001; 91: 1543-48.
17. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004; 22: 4762-71.
18. Sun W, Lipsitz S, Catalano P, Mailliard James A., Haller Daniel G. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005; 23: 4897-904
19. Ducreux MP, Boige V, Leboulleux S, Malka D, Kergoat P, Dromain C, et al. A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas. Oncology 2006; 70: 134-40.
20. Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari L, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 2007; 59: 637-42.
21. Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: The Rotterdam experience. Semin Nucl Med 2002; 32: 110-22.
22. Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002; 32: 123-32.
23. Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006; 36: 147-56.
24. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study. Ann Oncol 2001; 12: 941-5.
25. 90Y-DOTATOC. J Nucl Med 2002; 43: 610-16.
26. Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, et al. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med; 2001; 28: 426-34.
27. 90Y-DOTATOC in association with amino acid infusion: A phase I study. Eur J Nucl Med Mol Imaging 2003; 30: 207-16.
28. 3)octreotide in patients with somatostatin receptor positive tumours. Eur J Nucl Med Mol Imaging 2003; 30(Suppl 2): 232 (abstract).
29. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-30.
30. Teunissen JJ, Kwekkeboom DJ, de Jong M, Esser P, Valkema R, Krenning E. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 2005; 19: 595-616.
31. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTAOTyr3]octreotate: Comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med 2001; 28: 1319-25.
32. Prasad V, Fetscher S, Baum RP. Changing role of somatostatin receptor targeted drugs in NET: Nuclear Medicine's view. J Pharm Pharm Sci 2007; 10: 321s-337s.
33. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005; 46(Suppl 1): 62S-6S.
34. Teunissen JJ, Kwekkeboom DJ, Krenning EP. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate. J Clin Oncol 2004; 22: 2724-9.
35. Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP. Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 2007; 21: 111-29.
36. de Keizer B, van Aken MO, Feelders RA, de Herder WW, Kam BL, van Essen M, et al. Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2008; 35: 749-55.
37. van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, et al. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med 2006; 47: 1599-606.
38. Teunissen JJ, Kwekkeboom DJ, Krenning EP. Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs. Trends Endocrinol Metab 2006; 17: 19-25.
39. Chatal JF, Le Bodic MF, Kraeber-Bodéré F, Rousseau C, Resche I. Nuclear medicine applications for neuroendocrine tumors. World J Surg 2000; 24: 1285-9.
40. 90Y-labeled somatostatin analogs. J Nucl Med 2005; 46(Suppl 1): 13S-17S.
41. Slooter GD, Breeman WA, Marquet RL, Krenning EP, van Eijck CH. Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver. Int J Cancer 1999; 81: 767-71.
42. Kowalski J, Henze M, Schuhmacher J, Mäcke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003; 5: 42-8.
43. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48: 508-18.
44. Breeman WA, De Jong M, Visser TJ, Erion JL, Krenning EP. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 2003; 30: 917-20.
45. Chérel M, Davodeau F, Kraeber-Bodéré F, Chatal JF. Current status and perspectives in alpha radioimmunotherapy. QJ Nucl Med Mol Imaging 2006; 50: 322-9.
46. Sgouros G. Alpha-particles for targeted therapy. Adv Drug Deliv Rev. 2008; 60: 1402-6.
47. Okayasu R, Okada M, Okabe A, Noguchi M, Takakura K, Takahashi S. Repair of DNA damage induced by accelerated heavy ions in mammalian cells proficient and deficient in the non-homologous end-joining pathway. Radiat Res 2006; 165: 59-67.
48. 90Y-labeled CO17-1A fab' fragments in a human colonic cancer model. Cancer Res 1999; 59: 2635-43.
49. Nayak TK, Norenberg JP, Anderson TL, Prossnitz ER, Stabin MG, Atcher RW. Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells. Nucl Med Biol 2007; 34: 185-93.
50. Norenberg JP, Krenning BJ, Konings IR, Kusewitt DF, Nayak TK, Anderson TL, et al. 213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model. Clin Cancer Res 2006; 12: 897-903.
51. Haddad F, Ferrer L, Guertin A, Carlier T, Michel N, Barbet J, et al. ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine. Eur J Nucl Med Mol Imaging 2008; 35: 1377-87.
52. Vaidyanathan G, Boskovitz A, Shankar S, Zalutsky MR. Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers. Peptides 2004; 25: 2087-97.
53. Orlova A, Sjöstrom A, Lebeda O, Lundqvist H, Carlsson J, Tolmachev V. Targeting against epidermal growth factor receptors. Cellular processing of astatinated EGF after binding to cultured carcinoma cells. Anticancer Res 2004; 24: 4035-41.
54. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: Results and implications of the MAURITIUS trial. Semin Nucl Med 2002; 32: 148-55.
55. Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR, et al. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Current Pharmacy Design 2002; 8: 1781-807.
56. Schmid HA. Pasireotide (SOM230): Development, mechanism of action and potential applications. Mol Cell Endocrinol 2008; 286: 69-74.
57. Wehrmann C, Senftleben S, Zachert C, Müller D, Baum RP. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm 2007; 22: 406-16.
58. Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A 2006; 103: 16436-41.
59. Ginj M, Maecke HR. Synthesis of trifunctional somatostatin based derivatives for improved cellular and subcellular uptake. Tetrahedron Lett 2005; 46: 2821-4.
60. Ginj M, Hinni K, Tschumi S, Schulz S, Maecke HR. Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters. J Nucl Med 2005; 46: 2097-103.
61. McCluskey AG, Boyd M, Ross SC, Cosimo E, Clark AM, Angerson WJ, et al. [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumours expressing the noradrenaline transporter. Clin Cancer Res 2005; 11: 7929-37.
62. Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 2005; 20: 195-9.
63. Mastrangelo S, Tornesello A, Diociaiuti L, Pession A, Prete A, Rufini V, et al. Treatment of advanced neuroblastoma: Feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy. Br J Cancer 2001; 84: 460-4.
64. Kraeber-Bodéré F, Saï-Maurel C, Campion L, Faivre-Chauvet A, Mirallié E, Chérel M, et al. Enhanced antitumour activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Mol Cancer Ther 2002; 1: 267-74.
65. van Essen M, Krenning EP, Kam BL, de Herder WW, van Aken MO, Kwekkeboom DJ. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2008; 35: 743-8.
66. Madsen MT, Bushnell DL, Juweid ME, Menda Y, O'Dorisio MS, O'Dorisio T, et al. Potential increased tumour-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumours: A theoretic model. J Nucl Med 2006; 47: 660-7.
67. Terris B, Scoazec JY, Rubbia L, Bregeaud L, Pepper MS, Ruszniewski P, et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998; 32: 133-8.
68. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumour response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300: 1155-9.
69. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: A random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008; 26: 1316-23.
70. Gulec SA, Gaffga CM, Anthony CT, Su LJ, O'Leary JP, Woltering EA. Antiangiogenic therapy with somatostatin receptor-mediated in situ radiation. Am Surg 2001; 67: 1068-71.
71. Adams RL, Adams IP, Lindow SW, Zhong W, Atkin SL. Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer 2005; 92: 1493-8.
72. Dasgupta P. Somatostatin analogues: Multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 2004; 102: 61-85.
73. 90Y-DOTATOC and nephrotoxicity. Eur J Nucl Med. 2002; 29: 1543.
74. Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005; 46 (Suppl 1): 83S-91S.
75. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003; 30: 9-15.
76. Rolleman EJ, Bernard BF, Breeman WA, Forrer F, de Blois E, Hoppin J, et al. Molecular imaging of reduced renal uptake of radiolabelled [DOTA0,Tyr3]octreotate by the combination of lysine and Gelofusine in rats. Nuklearmedizin. 2008; 47: 110-5.
77. Vegt E, Wetzels JF, Russel FG, Masereeuw R, Boerman OC, van Eerd JE, et al. Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med 2006; 47: 432-6.
78. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in Peptide radionuclide receptor therapy: A review. J Nucl Med 2006; 47: 1467-75.
79. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-Specific Dosimetry in Predicting Renal Toxicity with 90Y-DOTATOC: Relevance of Kidney Volume and Dose Rate in Finding a Dose-Effect Relationship. J. Nucl. Med 2005; 46(Suppl 1): 99S - 106S.
80. Brogsitter C, Pinkert J, Bredow J, Kittner T, Kotzerke J. Enhanced tumor uptake in neuroendocrine tumors after intraarterial application of 131I-MIBG. J Nucl Med 2005; 46: 2112-6.
81. McStay MK, Maudgil D, Williams M, Tibballs JM, Watkinson AF, Caplin ME, et al. Large-volume liver metastases from neuroendocrine tumours: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology 2005; 237: 718-26.
82. Limouris GS, Chatziioannou A, Kontogeorgakos D, Mourikis D, Lyra M, Dimitriou P, et al. Selective hepatic arterial infusion of In-111-DTPA-Phe(1)-octreotide in neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging 2008; 35: 1827-37.
83. Schumacher T, Hofer S, Eichhorn K, Wasner M, Zimmerer S, Freitag P, et al. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: An extended pilot study. Eur J Nucl Med Mol Imaging 2002; 29: 486-93.
84. Kneifel S, Cordier D, Good S, Ionescu MC, Ghaffari A, Hofer S, et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p. Clin Cancer Res 2006; 12: 3843-50.
85. Melis M, Forrer F, Capello A, Bijster M, Bernard BF, Reubi JC, et al. Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy. QJ Nucl Med Mol Imaging 2007; 51: 324-33.
86. Schmitt A, Bernhardt P, Nilsson O, Ahlman H, Kölby L, Maecke HR, et al. Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal model. J Nucl Med 2004; 45: 1542-8.
87. Oddstig J, Bernhardt P, Nilsson O, Ahlman H, Forssell-Aronsson E. Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro. Nucl Med Biol 2006; 33: 841-6
88. Buchsbaum DJ, Chaudhuri TR, Zinn KR. Radiotargeted gene therapy. J Nucl Med 2005; 46(Suppl 1): 179S-86S.
89. Reubi JC. Targeting CCK receptors in human cancers. Curr Top Med Chem 2007; 7: 1239-42.
90. Behr TM. Béhé M. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med 2002; 32: 97-109.
91. Chen X, Park R, Hou Y, Tohme M, Shahinian AH, Bading JR, et al. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med 2004; 45: 1390-7.
92. Lantry LE, Cappelletti E, Maddalena ME, Fox JS, Feng W, Chen J, et al. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 2006; 47: 1144-52.
93. Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, Piccand V, et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. Nucl Med 2008; 49: 318-26.
94. 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med 2003; 30: 1134-9.
95. Mariani G, Erba PA, Signore A. Receptor-mediated tumor targeting with radiolabeled peptides: There is more to it than somatostatin analogs. J Nucl Med 2006; 47: 1904-7.
96. Körner M, Stöckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumours and human normal tissues: Potential for in vivo targeting. J Nucl Med 2007; 48: 736-43.
97. Wicki A, Wild D, Storch D, Seemayer C, Gotthardt M, Behe M, et al. Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res 2007; 13: 3696-705.
98. Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumour imaging. Mol Pharm 2006; 3: 472-87.